Medicines New Zealand is disappointed that patients will potentially miss out on a new medicine for a rare blood disorder known as PNH.
The new medicine Eculizumab is viewed as a life saving medicine by those suffering from the disorder.
Over 40 countries currently fund the treatment and the data certainly exists to confirm its efficacy, so patients will be the losers if PHARMAC proceeds with its interim decision not to fund this treatment.
We are however encouraged that for the first time PHARMAC has decided to consult the public about their decision before making the final decision.
People will have until late July to give their view, with a final decision expected in September or October.
"It is really encouraging that PHARMAC is actively seeking input from interested parties before making their final decision", Kevin Sheehy, General Manager of Medicines New Zealand says.